Literature DB >> 16458930

Characterisation of CGRP receptors in the human isolated middle meningeal artery.

Saurabh Gupta1, Suneet Mehrotra, Cees J J Avezaat, Carlos M Villalón, Pramod R Saxena, Antoinette Maassenvandenbrink.   

Abstract

Although the understanding of migraine pathophysiology is still incomplete, there seems to be little doubt that dilatation of cranial blood vessels, including meningeal arteries, is involved in the headache phase of migraine. Since calcitonin gene-related peptide (CGRP) has been implicated in this vasodilatation, the present study set out to compare the relaxant effects of the endogenous ligand h-alphaCGRP, and [ethylamide-Cys(2,7)]h-alphaCGRP ([Cys(Et)(2,7)]h-alphaCGRP), a CGRP(2) receptor agonist, on human isolated middle meningeal artery segments, precontracted with KCl. Classical Schild plot analysis was used to characterise the receptor population in this artery using BIBN4096BS and h-alphaCGRP(8-37) as antagonists. h-alphaCGRP relaxed arterial segments more potently than [Cys(Et)(2,7)]h-alphaCGRP (pEC(50): 8.51+/-0.16 and 7.48+/-0.24, respectively), while the maximal responses to these agonists were not significantly different. BIBN4096BS equipotently blocked the relaxations induced by both agonists with a pA(2) of approximately 10 and with a Schild plot slope not significantly different from unity. h-alphaCGRP(8-37) also antagonised the response to h-alphaCGRP with a pA(2) of 6.46+/-0.16 and a Schild plot slope not different from unity. Furthermore, the results obtained from RT-PCR studies confirmed the presence of all the essential components required for a functional CGRP(1) receptor in these arteries. Considering the high antagonist potency of BIBN4096BS, coupled to the lower agonist potency of [Cys (Et)(2,7)]h-alphaCGRP, it is reasonable to suggest a predominant role of CGRP(1) receptors in the human middle meningeal artery. This view is reinforced by Schild plot analysis, which revealed a slope of unity in all experiments, giving further evidence for a homogeneous CGRP receptor population in this vascular preparation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458930     DOI: 10.1016/j.lfs.2006.01.003

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Effect of CGRP and sumatriptan on the BOLD response in visual cortex.

Authors:  Mohammad S Asghar; Adam E Hansen; Henrik B W Larsson; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2012-01-14       Impact factor: 7.277

3.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

4.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

5.  Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery.

Authors:  Suneet Mehrotra; Saurabh Gupta; Ingrid M Garrelds; Carlos M Villalón; Pramod R Saxena; Ad J J C Bogers; Antoinette Maassenvandenbrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-14       Impact factor: 3.000

6.  Meningeal blood flow is controlled by H2 S-NO crosstalk activating a HNO-TRPA1-CGRP signalling pathway.

Authors:  Mária Dux; Christine Will; Birgit Vogler; Milos R Filipovic; Karl Messlinger
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

7.  Calcitonin gene-related peptide inhibits chemokine production by human dermal microvascular endothelial cells.

Authors:  Jing Huang; Lori L Stohl; Xi Zhou; Wanhong Ding; Richard D Granstein
Journal:  Brain Behav Immun       Date:  2011-02-18       Impact factor: 7.217

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 9.  Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.

Authors:  Andrea Stephanie Link; Anikó Kuris; Lars Edvinsson
Journal:  J Headache Pain       Date:  2008-01-23       Impact factor: 7.277

10.  Vascular actions of peripheral CGRP in migraine-like photophobia in mice.

Authors:  Bianca N Mason; Anne-Sophie Wattiez; Louis K Balcziak; Adisa Kuburas; William J Kutschke; Andrew F Russo
Journal:  Cephalalgia       Date:  2020-08-18       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.